Innovative Pharmacotherapeutic Strategies for Autoimmune and Inflammatory Disorders: Advancing Precision Medicine in Disease Management

ABSTRACT

Background: Autoimmune and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and psoriasis, are typified by immune dysregulation resulting in chronic inflammation and progressive tissue injury. Standard treatments, including corticosteroids, non-steroidal anti-inflammatory drugs, and disease-modifying anti-rheumatic drugs, are often of limited efficacy, have significant side effects, and are challenged by drug resistance. Objectives: This narrative review discusses new pharmacotherapeutic approaches to autoimmune and inflammatory diseases with a focus on biologic drugs, small-molecule inhibitors, gene therapy, and nanotechnology drug delivery systems. Methodology: A systematic literature search was performed using PubMed, Scopus, and Web of Science, covering clinical trials, pharmacological advances, and expert reviews of the past decade. The review highlights trends in immunotherapy, biomarker-stratified treatment selection, and new therapies for autoimmune diseases. Results: Biologic drugs, including tumor necrosis factor-alpha inhibitors, interleukin-17 inhibitors, and Janus kinase-signal transducer and activator of transcription inhibitors, have shown pertinent increases in disease remission rates and lowered systemic toxicity. However, constraints include high cost, resistance, and restricted access. Small-molecule inhibitors and precision immunotherapies enable patient-specific treatments with enhanced efficacy, but resistance and accessibility are significant hurdles. Breakthroughs in nanomedicine, clustered regularly interspaced short palindromic repeats-CRISPR associated protein 9 (CRISPR-Cas9) gene-editing, and artificial intelligence-assisted drug discovery hold much promise for overcoming these issues and providing more efficient and targeted treatments. Conclusion: Precision pharmacotherapy has transformed autoimmune disease treatment by providing mechanism-based, patient-specific approaches. Future studies should aim to improve biomarker-guided therapies, enhance drug accessibility, and incorporate AI-based innovations to maximize clinical outcomes.

KEYWORDS

• Biologic agents
• drug resistance
• inflammatory pathways
• targeted therapy

Showing references and in-text citations exactly as published.

• DOI10.1177/0976500X251398610Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Review · VOLUME 17, ISSUE 4Pharmacological Strategies in Cancer Immunotherapy: Advancing Immune Checkpoint Inhibitors, CAR-T Cell Therapies, and Cancer VaccinesVinay Kumar, Sadhana Misar Wajpeyi, Pankaj Yadav, Bhishmani Tarare · pp. 477–487Review ArticleSame type: Review
• Review · VOLUME 17, ISSUE 4Vestibular Stimulation as a Modulator of Metabolic Function: Implications for Diabetes Mellitus ManagementPaneer Selvam Pandian, Selvaraj Vinoth Kumar, Anupam Biswas, Usha Kumari, Subramani Parasuraman · pp. 499–506Review ArticleSame type: Review
• Review · VOLUME 17, ISSUE 4Therapeutic Targets in Management of Polycystic Ovary Syndrome (PCOS): A Comprehensive OverviewKapil Yadav, Rohit Malik, Nidhi Gehlawat, Namita Solanki, Syam Mohan, Siddig Ibrahim Abdelwahab, Manal Mohamed Elhassan Taha, Abdullah Farasani, Jobran M. Moshi, Ahmad Assiri, Saeed Alshahrani, Khaled A. Sahli, Hussam M. Shubaily, Marwa Qadri, Amani Khardali, Waseem Hassan · pp. 507–517Review ArticleSame type: Review